Oncology latest news

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%

Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and prophylactic strategies

· 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance

· Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma · Fifth positive Phase 3 study evaluating Johnson & Johnson’s multiple myeloma T-cell therapy portfolio in second line, further strengthening the company’s leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

• Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death • Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine

• More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication • RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting • Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication

• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes • ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations